Corporate | 17 February 2012 07:00

Cytos Biotechnology Ltd announces full year 2011 financial results

Cytos Biotechnology AG / Key word(s): Final Results

17.02.2012 / 07:00

Schlieren (Zurich), Switzerland, February 17, 2012 – Cytos Biotechnology Ltd (SIX:CYTN) today presented its full year 2011 financial results.

The complete press release as well as the Annual Report 2011 can be downloaded on Cytos Biotechnology’s website ( www.cytos.com ).

For further information please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel.: +41 44 733 46 46
e-Mail: harry.welten@cytos.com
Website: www.cytos.com

About Cytos Biotechnology Ltd
Cytos Biotechnology Ltd is a Swiss public biotechnology company that specializes in the development and commercialization of a new class of biopharmaceutical products – the Immunodrugs(TM). Immunodrugs(TM) are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs(TM) are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Immunodrug(TM) candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss Exchange (SIX:’CYTN’).

End of Corporate News

17.02.2012 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies.
The Swiss news archive can be found at http://www.equitystory.ch/nachrichten

Language:	English
Company:	Cytos Biotechnology AG
	Wagistr. 25
	8952 Schlieren
	Switzerland
Phone:	+41 44 733 4747
Fax:	+41 44 733 4740
E-mail:	info@cytos.com
Internet:	www.cytos.com
ISIN:	CH0011025217, CH0029060735
Swiss Security Number:	–
Listed:	Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt; SIX

End of News EquityStory AG News-Service

157148  17.02.2012